Cannabinoid-opioid interactions during neuropathic pain and analgesia

Current Opinion in Pharmacology

Volumn 10, Issue 1, 2010, Pages 80-86

  Bushlin, Ittai ^a   Rozenfeld, Raphael ^a   Devi, Lakshmi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BETA ENDORPHIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CP 55 490; DELTA OPIATE RECEPTOR; DYNORPHIN; ENDOCANNABINOID; ENKEPHALIN; G PROTEIN COUPLED RECEPTOR; KAPPA OPIATE RECEPTOR; LIGAND; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE; OPIATE AGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANALGESIA; ANTINOCICEPTION; CHRONIC PAIN; CLINICAL FEATURE; CONSTIPATION; DRUG CROSS TOLERANCE; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; LOW DRUG DOSE; MOLECULAR INTERACTION; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; RESPIRATION DEPRESSION; REVIEW;

ANALGESICS, OPIOID; ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; NEURALGIA; PAIN; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID;

EID: 72449158814     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.09.009     Document Type: Review

References (70)

1. Foley K.M. Opioids and chronic neuropathic pain. N Engl J Med 348 (2003) 1279-1281
2. Eisenberg E., McNicol E.D., and Carr D.B. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 293 (2005) 3043-3052
3. Finnerup N.B., Sindrup S.H., and Jensen T.S. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundam Clin Pharmacol 21 (2007) 129-136
4. Jensen M.P., Hoffman A.J., and Cardenas D.D. Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. Spinal Cord 43 (2005) 704-712
5. Welch S.P. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 21 (2009) 143-151
6. Kieffer B.L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 15 (1995) 615-635
7. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
8. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20 (1999) 287-294
9. Cichewicz D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74 (2004) 1317-1324
10. Hohmann A.G., Briley E.M., and Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 822 (1999) 17-25
11. 1R and MOR on individual neurons within the dorsal horn the spinal cord, by immunoelectron microscopy.
12. Vigano D., Rubino T., and Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81 (2005) 360-368
13. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22 (2002) 1146-1154
14. Castane A., Robledo P., Matifas A., Kieffer B.L., and Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 17 (2003) 155-159
15. Valverde O., Ledent C., Beslot F., Parmentier M., and Roques B.P. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12 (2000) 533-539
16. Houser S.J., Eads M., Embrey J.P., and Welch S.P. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res 857 (2000) 337-342
17. Mason Jr. D.J., Lowe J., and Welch S.P. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol 378 (1999) 237-248
18. Pugh Jr. G., Mason Jr. D.J., Combs V., and Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther 281 (1997) 730-737
19. Smith P.B., Welch S.P., and Martin B.R. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 268 (1994) 1381-1387
20. Reche I., Ruiz-Gayo M., and Fuentes J.A. Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. Neuropharmacology 37 (1998) 215-222
21. Corchero J., Avila M.A., Fuentes J.A., and Manzanares J. delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 61 (1997) PL39-43
22. Corchero J., Fuentes J.A., and Manzanares J. delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol 323 (1997) 193-195
23. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 55 (1998) 126-132
24. 1R with the selective antagonist AM251 abolishes the antinociceptive effects of morphine in a peripheral inflammatory pain model.
25. da Fonseca Pacheco D., Klein A., Perez A.C., da Fonseca Pacheco C.M., de Francischi J.N., Lopes Reis G.M., and Duarte I.D. Central antinociception induced by micro-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB receptor. Br J Pharmacol 158 (2009) 225-231
26. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., and Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26 (2006) 13318-13327. Use of FAAH inhibitors to increase endocannabinoid levels in the spinal cord attenuates mechanical pain in an animal experiencing neuropathic pain. Interestingly, the authors demonstrate the role of opioid receptors (and endogenous opioid peptides by extension) in the antinociceptive effects of FAAH inhibitors as these effects can be blocked by naloxone.
27. Schlosburg J.E., Kinsey S.G., and Lichtman A.H. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 11 (2009) 39-44
28. 2R can lead to beta-endorphin release from keratinocytes. This supports a role for endogenous opioid peptide release in the antinociceptive actions of cannabinoid receptor agonists.
29. Thorat S.N., and Bhargava H.N. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 260 (1994) 5-13
30. Rubino T., Tizzoni L., Vigano D., Massi P., and Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 8 (1997) 3219-3223
31. Vigano D., Rubino T., Vaccani A., Bianchessi S., Marmorato P., Castiglioni C., and Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 182 (2005) 527-536
32. Vasquez C., and Lewis D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19 (1999) 9271-9280
33. Robledo P., Berrendero F., Ozaita A., and Maldonado R. Advances in the field of cannabinoid-opioid cross-talk. Addict Biol 13 (2008) 213-224
34. Maldonado R., and Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharmacol 13 (2003) 401-410
35. Valverde O., Maldonado R., Valjent E., Zimmer A.M., and Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20 (2000) 9284-9289
36. Tham S.M., Angus J.A., Tudor E.M., and Wright C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 144 (2005) 875-884. Combinations of opioid and cannabinoid agonists can induce synergistic analgesia in an animal experiencing acute pain. The extension of these studies to models of chronic pain is essential for evaluating the potential of combining therapies for this disease state.
37. Cichewicz D.L., Haller V.L., and Welch S.P. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 297 (2001) 121-127
38. Rashid M.H., Inoue M., Toda K., and Ueda H. Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther 309 (2004) 380-387
39. Lim G., Sung B., Ji R.R., and Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105 (2003) 275-283
40. Mitrirattanakul S., Ramakul N., Guerrero A.V., Matsuka Y., Ono T., Iwase H., Mackie K., Faull K.F., and Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126 (2006) 102-114
41. Walczak J.S., Pichette V., Leblond F., Desbiens K., and Beaulieu P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132 (2005) 1093-1102
42. Siegling A., Hofmann H.A., Denzer D., Mauler F., and De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415 (2001) R5-7
43. Obara I., Parkitna J.R., Korostynski M., Makuch W., Kaminska D., Przewlocka B., and Przewlocki R. Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain 141 (2009) 283-291
44. Zhang X., Bao L., Shi T.J., Ju G., Elde R., and Hokfelt T. Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience 82 (1998) 223-240
45. Puehler W., Zollner C., Brack A., Shaqura M.A., Krause H., Schafer M., and Stein C. Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. Neuroscience 129 (2004) 473-479
46. Besse D., Lombard M.C., Perrot S., and Besson J.M. Regulation of opioid binding sites in the superficial dorsal horn of the rat spinal cord following loose ligation of the sciatic nerve: comparison with sciatic nerve section and lumbar dorsal rhizotomy. Neuroscience 50 (1992) 921-933
47. Ozaki S., Narita M., Narita M., Iino M., Miyoshi K., and Suzuki T. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience 116 (2003) 89-97
48. 1R knockout animals during the development of neuropathic pain. While MOR mRNA is decreased in both wild-type and CB1R knockout animals, DOR and KOR mRNA are unchanged after partial sciatic nerve lesion in both genotypes.
49. Wang Z., Gardell L.R., Ossipov M.H., Vanderah T.W., Brennan M.B., Hochgeschwender U., Hruby V.J., Malan Jr. T.P., Lai J., and Porreca F. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 21 (2001) 1779-1786
50. Sung B., Loh H.H., and Wei L. Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury. Neurosci Lett 291 (2000) 163-166
51. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., and MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
52. Rodriguez J.J., Mackie K., and Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21 (2001) 823-833
53. Kathmann M., Flau K., Redmer A., Trankle C., and Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 354-361
54. Vaysse P.J., Gardner E.L., and Zukin R.S. Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 241 (1987) 534-539
55. Shapira M., Gafni M., and Sarne Y. Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. Brain Res 806 (1998) 26-35
56. Rios C., Gomes I., and Devi L.A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148 (2006) 387-395. First study to show direct, biophysical interactions between opioid and cannabinoid receptors, in cotransfected cells. The authors also find antagonistic interactions between the two receptor types in cotransfected cells and in native tissue exposed to increasing concentrations of an agonist to one receptor along with nonactivating concentrations of an agonist of the other receptor.
57. Daniels D.J., Lenard N.R., Etienne C.L., Law P.Y., Roerig S.C., and Portoghese P.S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102 (2005) 19208-19213
58. Peng X., Knapp B.I., Bidlack J.M., and Neumeyer J.L. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. J Med Chem 49 (2006) 256-262
59. Maekawa K., Minami M., Masuda T., and Satoh M. Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Pain 64 (1996) 365-371
60. Iadarola M.J., Brady L.S., Draisci G., and Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 35 (1988) 313-326
61. Millan M.J., Czlonkowski A., Morris B., Stein C., Arendt R., Huber A., Hollt V., and Herz A. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain 35 (1988) 299-312
62. Stevens C.W., Kajander K.C., Bennett G.J., and Seybold V.S. Bilateral and differential changes in spinal mu, delta and kappa opioid binding in rats with a painful, unilateral neuropathy. Pain 46 (1991) 315-326
63. Holdridge S.V., and Cahill C.M. Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Eur J Pain 11 (2007) 685-693
64. Stone L.S., Vulchanova L., Riedl M.S., Williams F.G., Wilcox G.L., and Elde R. Effects of peripheral nerve injury on delta opioid receptor (DOR) immunoreactivity in the rat spinal cord. Neurosci Lett 361 (2004) 208-211
65. Tseng T.J., Chen C.C., Hsieh Y.L., and Hsieh S.T. Influences of surgical decompression on the dorsal horn after chronic constriction injury: changes in peptidergic and delta-opioid receptor (+) nerve terminals. Neuroscience 156 (2008) 758-768
66. Li J.L., Kaneko T., and Mizuno N. Effects of peripheral nerve ligation on expression of mu-opioid receptor in sensory ganglion neurons: an immunohistochemical study in dorsal root and nodose ganglion neurons of the rat. Neurosci Lett 214 (1996) 91-94
67. Truong W., Cheng C., Xu Q.G., Li X.Q., and Zochodne D.W. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann Neurol 53 (2003) 366-375
68. Porreca F., Tang Q.B., Bian D., Riedl M., Elde R., and Lai J. Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res 795 (1998) 197-203
69. Robertson B., Schulte G., Elde R., and Grant G. Effects of sciatic nerve injuries on delta-opioid receptor and substance P immunoreactivities in the superficial dorsal horn of the rat. Eur J Pain 3 (1999) 115-129
70. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., and O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 (2003) 2750-2754